<DOC>
	<DOC>NCT01978600</DOC>
	<brief_summary>The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension.</brief_summary>
	<brief_title>Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description>This study consisted of two phases, a Screening/Eligibility Phase and a Treatment Phase. Both phases required the patient to complete an overnight stay.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>Clinical diagnosis of either openangle glaucoma or ocular hypertension in both eyes. Willing and able to attend all studyrelated visits and be housed overnight at clinical site for the study assessments. Must sign an Informed Consent form. Other protocolspecified inclusion criteria may apply. Women of childbearing potential if pregnant, breastfeeding, or not using adequate birth control. Severe central visual field loss in either eye. Chronic, recurrent or severe inflammatory eye disease. Ocular trauma or ocular surgery within the past 6 months. Ocular infection or ocular inflammation within the past 3 months. Clinically significant or progressive retinal disease. Other ocular pathology, including severe dry eye, that may in the opinion of the investigator preclude the administration of study medication. Any other conditions including severe illness which would make the patient, in the opinion of the Investigator, unsuitable for the study. Any medical condition that would preclude the safe administration of a topical betablocker. Cannot safely discontinue all glucocorticoids administered by any route. Other protocolspecified exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>Simbrinza™</keyword>
	<keyword>Intraocular Pressure</keyword>
</DOC>